Şunu aradınız:: brimonidine (Maltaca - İngilizce)

brinzolamide + brimonidine medjaa
brinzolamide + brimonidine meana

mirvaso 3 mg/g ġell brimonidine
mirvaso 3 mg/g gel brimonidine

is-sustanza attiva hi brimonidine.
the active substance is brimonidine.

brimonidine huwa metabolizzat b’mod estensiv mill-fwied.
brimonidine is extensively metabolised by the liver.

brimonidine huwa eliminat primarjament fl-awrina bħala metaboliti.
brimonidine is primarily eliminated in the urine as metabolites.

wara għoti topiku brimonidine huwa assorbit malajr fl-għajn.
brimonidine is rapidly absorbed into the eye following topical administration.

3 reazzjoni avversa addizzjonali osservata b’monoterapija ta’ brimonidine
3 additional adverse reaction observed with brimonidine monotherapy

1 ml ta’ suspensjoni fih 10 mg brinzolamide u 2 mg brimonidine tartrate
1 ml of suspension contains 10 mg brinzolamide and 2 mg brimonidine tartrate

brimonidine mogħti mill-ħalq huwa eliminat fil-ħalib tas- sider.
brimonidine administered orally is excreted in breast milk.

barra dan, għoti ta’ brimonidine jwassal għal żieda fil-ħruġ uveosklerali.
additionally, administration of brimonidine results in an increase in uveoscleral outflow.

effetti sekondarji serji ġew irrappurtati fi tfal li bi żball belgħu mediċini li fihom brimonidine.
serious side effects have been reported in children who accidently swallowed medicines containing brimonidine.

l-effett li jbaxxi l-iop ta’ brimonidine jista’ jkun itwal.
the iop-lowering effect of brimonidine may be longer.

dejta mhux klinika ma turi l-ebda effetti ta’ brinzolamide jew brimonidine fuq il-fertilità.
nonclinical data do not show any effects of brinzolamide or brimonidine on fertility.

l-użu ta’ brimonidine ġie assoċjat ma’ tnaqqis minimu fil-pressjoni tad-demm.
the use of brimonidine has been associated with minimal decreases in blood pressure.

simbrinza huwa soluzzjoni għat-taqtir fl-għajnejn li fiha żewġ sustanzi attivi: brinzolamide u brimonidine tartrate.
simbrinza is an eye drop solution that contains two active substances: brinzolamide and brimonidine tartrate.

b’kuntrast ma’ dan, brimonidine juri farmakokinetika lineari fuq il-firxa ta’ doża klinika terapewtika.
in contrast, brimonidine exhibits linear pharmacokinetics over the clinically therapeutic dose range.

hemm informazzjoni limitata ħafna dwar teħid aċċidentali mill-ħalq bil-komponent brimonidine ta’ simbrinza fl-adulti.
there is very limited information regarding accidental ingestion with the brimonidine component of simbrinza in adults.

brimonidine ma wera l-ebda periklu speċjali fuq is-sistema riproduttiva jew fuq l-iżvilupp fi speċi ta’ annimali.
brimonidine did not present any special reproductive or developmental hazard in animal species.

il-brimonidine jżid ukoll id-drenaġġ tal-aqueous humour min-naħa ta’ quddiem tal-għajn.
brimonidine also increases the drainage of aqueous humour from the front of the eye.

1 ml ta’ suspensjoni fih 10 mg ta’ brinzolamide u 2 mg ta’ brimonidine tartrate ekwivalenti għal 1.3 mg ta’ brimonidine.
1 ml of suspension contains 10 mg of brinzolamide and 2 mg of brimonidine tartrate equivalent to 1.3 mg of brimonidine.